[Genomic instability in atherosclerosis].

Dzhokhadze TA, Buadze TZh, Gaiozishvili MN, Kakauridze NG, Lezhava TA

Georgian medical news1 Nov 2014

PMID25541832PepBankPUB-25541832

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Efficacy outcome
In atherosclerosis patient lymphocyte cultures, Livagen alone normalized altered chromosome aberration indicators in both age groups.
In plain wordsIn lab tests with atherosclerosis lymphocytes, Livagen alone normalized chromosome aberration indicators in both age groups.
Peptide
Livagen (KEDA)
Outcome
DecreaseChromosome aberrations
Study
humann: not reported in source
Lymphocyte cultures from atherosclerosis patients in both age groups
Outcome group
Genome stability · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
It was also shown that Livagen (characterized by modifying influence on chromatin) separately and in combination with cobalt ions, promotes normalization of altered genomic indicators of atherosclerosis in both age groups.
3 context sentences(design, population, supporting numbers)
Summary · context
A comparative study of the level of genomic instability, parameters of quantitative and structural mutations of chromosomes (aberration, aneuploidy, polyploidy) in lymphocyte cultures from patients with atherosclerosis of age 80 years and older (control group - 30-35 years old) was conducted.
Summary · context
The possibility of correction of disturbed genomic indicators by peptide bioregulators - Livagen (Lys-Glu-Asp-Ala) and cobalt ions with separate application or in combination was also studied.
Summary · context
Control was lymphocyte culture of two healthy respective age groups.
Report a problemFND-2554183201
02LabIn vitro (cells)Efficacy outcome
In atherosclerosis patient lymphocyte cultures, Livagen alone normalized altered aneuploidy indicators in both age groups.
In plain wordsIn lab tests with atherosclerosis lymphocytes, Livagen alone normalized aneuploidy indicators in both age groups.
Peptide
Livagen (KEDA)
Outcome
DecreaseAneuploidy
Study
humann: not reported in source
Lymphocyte cultures from atherosclerosis patients in both age groups
Outcome group
Genome stability · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
It was also shown that Livagen (characterized by modifying influence on chromatin) separately and in combination with cobalt ions, promotes normalization of altered genomic indicators of atherosclerosis in both age groups.
3 context sentences(design, population, supporting numbers)
Summary · context
A comparative study of the level of genomic instability, parameters of quantitative and structural mutations of chromosomes (aberration, aneuploidy, polyploidy) in lymphocyte cultures from patients with atherosclerosis of age 80 years and older (control group - 30-35 years old) was conducted.
Summary · context
The possibility of correction of disturbed genomic indicators by peptide bioregulators - Livagen (Lys-Glu-Asp-Ala) and cobalt ions with separate application or in combination was also studied.
Summary · context
Control was lymphocyte culture of two healthy respective age groups.
Report a problemFND-2554183202
03LabIn vitro (cells)Efficacy outcome
In atherosclerosis patient lymphocyte cultures, Livagen alone normalized altered polyploidy indicators in both age groups.
In plain wordsIn lab tests with atherosclerosis lymphocytes, Livagen alone normalized polyploidy indicators in both age groups.
Peptide
Livagen (KEDA)
Outcome
DecreasePolyploidy
Study
humann: not reported in source
Lymphocyte cultures from atherosclerosis patients in both age groups
Outcome group
Genome stability · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
It was also shown that Livagen (characterized by modifying influence on chromatin) separately and in combination with cobalt ions, promotes normalization of altered genomic indicators of atherosclerosis in both age groups.
3 context sentences(design, population, supporting numbers)
Summary · context
A comparative study of the level of genomic instability, parameters of quantitative and structural mutations of chromosomes (aberration, aneuploidy, polyploidy) in lymphocyte cultures from patients with atherosclerosis of age 80 years and older (control group - 30-35 years old) was conducted.
Summary · context
The possibility of correction of disturbed genomic indicators by peptide bioregulators - Livagen (Lys-Glu-Asp-Ala) and cobalt ions with separate application or in combination was also studied.
Summary · context
Control was lymphocyte culture of two healthy respective age groups.
Report a problemFND-2554183203

Studies that did not test the peptide alone3

In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Livagen (KEDA).

04LabNot a test of Livagen (KEDA) aloneIn vitro (cells)Efficacy outcome
In atherosclerosis patient lymphocyte cultures, Livagen with cobalt normalized altered chromosome aberration indicators in both age groups.
In plain wordsIn lab tests with atherosclerosis lymphocytes, Livagen with cobalt normalized chromosome aberration indicators in both age groups.
Peptide
Livagen (KEDA)
Outcome
DecreaseChromosome aberrations
Study
humann: not reported in source
Lymphocyte cultures from atherosclerosis patients in both age groups
Outcome group
Genome stability · Cardiovascular
Source sentences
Summary
It was also shown that Livagen (characterized by modifying influence on chromatin) separately and in combination with cobalt ions, promotes normalization of altered genomic indicators of atherosclerosis in both age groups.
3 context sentences(design, population, supporting numbers)
Summary · context
A comparative study of the level of genomic instability, parameters of quantitative and structural mutations of chromosomes (aberration, aneuploidy, polyploidy) in lymphocyte cultures from patients with atherosclerosis of age 80 years and older (control group - 30-35 years old) was conducted.
Summary · context
The possibility of correction of disturbed genomic indicators by peptide bioregulators - Livagen (Lys-Glu-Asp-Ala) and cobalt ions with separate application or in combination was also studied.
Summary · context
Control was lymphocyte culture of two healthy respective age groups.
In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).
Report a problemFND-2554183204
05LabNot a test of Livagen (KEDA) aloneIn vitro (cells)Efficacy outcome
In atherosclerosis patient lymphocyte cultures, Livagen with cobalt normalized altered aneuploidy indicators in both age groups.
In plain wordsIn lab tests with atherosclerosis lymphocytes, Livagen with cobalt normalized aneuploidy indicators in both age groups.
Peptide
Livagen (KEDA)
Outcome
DecreaseAneuploidy
Study
humann: not reported in source
Lymphocyte cultures from atherosclerosis patients in both age groups
Outcome group
Genome stability · Cardiovascular
Source sentences
Summary
It was also shown that Livagen (characterized by modifying influence on chromatin) separately and in combination with cobalt ions, promotes normalization of altered genomic indicators of atherosclerosis in both age groups.
3 context sentences(design, population, supporting numbers)
Summary · context
A comparative study of the level of genomic instability, parameters of quantitative and structural mutations of chromosomes (aberration, aneuploidy, polyploidy) in lymphocyte cultures from patients with atherosclerosis of age 80 years and older (control group - 30-35 years old) was conducted.
Summary · context
The possibility of correction of disturbed genomic indicators by peptide bioregulators - Livagen (Lys-Glu-Asp-Ala) and cobalt ions with separate application or in combination was also studied.
Summary · context
Control was lymphocyte culture of two healthy respective age groups.
In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).
Report a problemFND-2554183205
06LabNot a test of Livagen (KEDA) aloneIn vitro (cells)Efficacy outcome
In atherosclerosis patient lymphocyte cultures, Livagen with cobalt normalized altered polyploidy indicators in both age groups.
In plain wordsIn lab tests with atherosclerosis lymphocytes, Livagen with cobalt normalized polyploidy indicators in both age groups.
Peptide
Livagen (KEDA)
Outcome
DecreasePolyploidy
Study
humann: not reported in source
Lymphocyte cultures from atherosclerosis patients in both age groups
Outcome group
Genome stability · Cardiovascular
Source sentences
Summary
It was also shown that Livagen (characterized by modifying influence on chromatin) separately and in combination with cobalt ions, promotes normalization of altered genomic indicators of atherosclerosis in both age groups.
3 context sentences(design, population, supporting numbers)
Summary · context
A comparative study of the level of genomic instability, parameters of quantitative and structural mutations of chromosomes (aberration, aneuploidy, polyploidy) in lymphocyte cultures from patients with atherosclerosis of age 80 years and older (control group - 30-35 years old) was conducted.
Summary · context
The possibility of correction of disturbed genomic indicators by peptide bioregulators - Livagen (Lys-Glu-Asp-Ala) and cobalt ions with separate application or in combination was also studied.
Summary · context
Control was lymphocyte culture of two healthy respective age groups.
In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).
Report a problemFND-2554183206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 17:05 UTC
Study results updated
Version 1
21 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.